{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromatosis+Type+1&page=3",
    "query": {
      "condition": "Neurofibromatosis Type 1",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 182,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromatosis+Type+1&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromatosis+Type+1&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T18:55:06.817Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05489783",
      "title": "Glioma Developmental and HyperActive Ras Tumor (DHART) Board",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2022-07-29",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05489783"
    },
    {
      "nct_id": "NCT00657202",
      "title": "Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis Type 1",
        "Cutaneous Neurofibromas"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2008-03",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657202"
    },
    {
      "nct_id": "NCT02944032",
      "title": "Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurofibromatosis Type 1"
      ],
      "interventions": [
        {
          "name": "CogmedRM",
          "type": "OTHER"
        },
        {
          "name": "Mobymax",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kristina Hardy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "8 Years to 16 Years"
      },
      "enrollment_count": 103,
      "start_date": "2016-05",
      "completion_date": "2021-09-27",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02944032"
    },
    {
      "nct_id": "NCT01880749",
      "title": "Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis Type 2",
        "Vestibular Schwannomas",
        "Meningiomas"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2013-06",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01880749"
    },
    {
      "nct_id": "NCT05253131",
      "title": "Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MPNST",
        "NF1",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Selumetinib + ZEN-3694 ± Durvalumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 41,
      "start_date": "2026-08-04",
      "completion_date": "2032-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05253131"
    },
    {
      "nct_id": "NCT06502171",
      "title": "Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis 1",
        "Plexiform Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Selumetinib Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Girish Dhall, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-09",
      "completion_date": "2034-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06502171"
    },
    {
      "nct_id": "NCT04481048",
      "title": "Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis 1"
      ],
      "interventions": [
        {
          "name": "N-Acetyl cysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "8 Years to 16 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-02-23",
      "completion_date": "2024-06-25",
      "has_results": true,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04481048"
    },
    {
      "nct_id": "NCT05521048",
      "title": "Doxycycline in Cutaneous Schwannoma (NF2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 2"
      ],
      "interventions": [
        {
          "name": "Doxycycline Injection [Doxy]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2022-09-19",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05521048"
    },
    {
      "nct_id": "NCT06188741",
      "title": "Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis 1",
        "Plexiform Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "1 Year to 8 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-08-27",
      "completion_date": "2032-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06188741"
    },
    {
      "nct_id": "NCT00846430",
      "title": "Medical Treatment of \"High-Risk\" Neurofibromas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis 1"
      ],
      "interventions": [
        {
          "name": "Peg-Interferon alpha-2b",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib (Celebrex)",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (temodar)",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate (Oncovin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health West",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 9,
      "start_date": "2008-10",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-10-06T18:55:06.817Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00846430"
    }
  ]
}